BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23530090)

  • 1. Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system.
    Henderson CJ; McLaughlin LA; Wolf CR
    Mol Pharmacol; 2013 Jun; 83(6):1209-17. PubMed ID: 23530090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of hepatic cytochrome b
    Reed L; Indra R; Mrizova I; Moserova M; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Toxicol Appl Pharmacol; 2019 Mar; 366():64-74. PubMed ID: 30685480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome b
    Reed L; Mrizova I; Barta F; Indra R; Moserova M; Kopka K; Schmeiser HH; Wolf CR; Henderson CJ; Stiborova M; Phillips DH; Arlt VM
    Arch Toxicol; 2018 Apr; 92(4):1625-1638. PubMed ID: 29368147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling.
    Arlt VM; Poirier MC; Sykes SE; John K; Moserova M; Stiborova M; Wolf CR; Henderson CJ; Phillips DH
    Toxicol Lett; 2012 Sep; 213(2):160-6. PubMed ID: 22759596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation and detoxification metabolism of urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone by rat and mouse hepatic microsomes.
    Stiborova M; Cechova T; Borek-Dohalska L; Moserova M; Frei E; Schmeiser HH; Paca J; Arlt VM
    Neuro Endocrinol Lett; 2012; 33 Suppl 3():8-15. PubMed ID: 23353838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining the in Vivo Role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5.
    Finn RD; McLaughlin LA; Ronseaux S; Rosewell I; Houston JB; Henderson CJ; Wolf CR
    J Biol Chem; 2008 Nov; 283(46):31385-93. PubMed ID: 18805792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions.
    Stiborová M; Moserová M; Černá V; Indra R; Dračínský M; Šulc M; Henderson CJ; Wolf CR; Schmeiser HH; Phillips DH; Frei E; Arlt VM
    Toxicology; 2014 Apr; 318():1-12. PubMed ID: 24530354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice.
    Arlt VM; Stiborová M; Henderson CJ; Thiemann M; Frei E; Aimová D; Singh R; Gamboa da Costa G; Schmitz OJ; Farmer PB; Wolf CR; Phillips DH
    Carcinogenesis; 2008 Mar; 29(3):656-65. PubMed ID: 18204078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells.
    Heintze T; Klein K; Hofmann U; Zanger UM
    Sci Rep; 2021 Jan; 11(1):1000. PubMed ID: 33441761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
    Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
    Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the hepatic CYP reductase null mouse model and its potential application in drug discovery.
    Boggs JW; Hop CE; McNamara E; Deng Y; Messick K; West K; Choo EF
    Mol Pharm; 2014 Mar; 11(3):1062-8. PubMed ID: 24450768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
    Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
    Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse.
    Stiborová M; Arlt VM; Henderson CJ; Wolf CR; Kotrbová V; Moserová M; Hudecek J; Phillips DH; Frei E
    Toxicol Appl Pharmacol; 2008 Feb; 226(3):318-27. PubMed ID: 17976674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome b5.
    Peyronneau MA; Renaud JP; Truan G; Urban P; Pompon D; Mansuy D
    Eur J Biochem; 1992 Jul; 207(1):109-16. PubMed ID: 1628642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome b₅ reductase-cytochrome b₅ as an active P450 redox enzyme system in Phanerochaete chrysosporium: atypical properties and in vivo evidence of electron transfer capability to CYP63A2.
    Syed K; Kattamuri C; Thompson TB; Yadav JS
    Arch Biochem Biophys; 2011 May; 509(1):26-32. PubMed ID: 21376009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the metabolism of midazolam in C57BL/6J and hepatic reductase null (HRN) mice.
    Grimsley A; Foster A; Gallagher R; Hutchison M; Lundqvist A; Pickup K; Wilson ID; Samuelsson K
    Biochem Pharmacol; 2014 Dec; 92(4):701-11. PubMed ID: 25450676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
    Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
    Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity.
    Pearce RE; McIntyre CJ; Madan A; Sanzgiri U; Draper AJ; Bullock PL; Cook DC; Burton LA; Latham J; Nevins C; Parkinson A
    Arch Biochem Biophys; 1996 Jul; 331(2):145-69. PubMed ID: 8660694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes.
    Yamazaki H; Nakano M; Gillam EM; Bell LC; Guengerich FP; Shimada T
    Biochem Pharmacol; 1996 Jul; 52(2):301-9. PubMed ID: 8694855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome
    Kim D; Kim V; Tateishi Y; Guengerich FP
    Drug Metab Dispos; 2021 Oct; 49(10):902-909. PubMed ID: 34330716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.